UNSPSC 51141514: Zonisamide

This classification denotes an anticonvulsant agent with the molecular formula C8H8N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 459384H98V, chemically known as 1,2-benzisoxazole-3-methanesulfonamide but generally known as zonisamide, which bears US NIH Compound Identifier 5734. European Medicines Agency schedules Zonisamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00187MIG.

UNSPSC 51141514 Zonisamide is a Commodity code that nominally covers a specific antiepileptic pharmaceutical product, but recent state and local procurement activity under this code shows little direct relevance to zonisamide specifically. Instead, the opportunities posted show state and local buyers procuring a broader range of pharmaceuticals, over-the-counter products, and pharmacy-related services. Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and drug deactivation systems (1,900 units of naloxone and 800 drug deactivation systems annually) with quarterly deliveries to the county's community health building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to supply state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026, and contract award effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, regarding direct-to-manufacturer prescription programs to explore vendor capabilities for establishing relationships outside traditional pharmacy benefit manager and wholesale channels. These opportunities reflect solicitations for commodity pharmaceuticals, emergency-response medications, and pharmacy program administration rather than zonisamide procurement in particular.

The code shows activity across state health agencies, county health departments, and multistate cooperative purchasing entities. Seminole County's procurement was funded through FEMA and required quarterly deliveries, fixed-fee pricing, E-Verify compliance, and insurance coverages including $2 million in professional liability. The MMCAP RFP required vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act compliance, carry $5 million in commercial general liability and $2 million in network security and privacy liability, and accept a 3 percent administrative fee on all purchases. The Texas RFI was exploratory in nature, seeking market intelligence on direct-to-manufacturer contracting models without formal evaluation criteria or binding timelines. Geographic activity centered on Florida, Minnesota, Oregon, and Texas. The mismatch between the code's nominal scope (zonisamide) and actual procurement activity suggests this code may not align reliably with state and local pharmaceutical buying patterns as currently practiced.